Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in Clinical Research
May 30, 2024 07:00 ET
|
Fortrea Holdings Inc
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced its comprehensive and integrated...
Fortrea Appoints Machelle Sanders to Board of Directors
May 16, 2024 16:05 ET
|
Fortrea Holdings Inc
DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the appointment of Machelle Sanders to...
Fortrea Reports First Quarter 2024 Results
May 13, 2024 06:30 ET
|
Fortrea Holdings Inc
For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 millionGAAP net loss of $81.6 millionAdjusted EBITDA of $29.5 millionGAAP and adjusted diluted earnings...
Fortrea Reschedules Release of First Quarter 2024 Financial Results and Conference Call
May 06, 2024 08:22 ET
|
Fortrea Holdings Inc
DURHAM, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced an updated issuance date for the...
Fortrea Announces Date for First Quarter 2024 Financial Results and Conference Call
April 11, 2024 07:00 ET
|
Fortrea Holdings Inc
DURHAM, N.C., April 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter...
Fortrea חותמת על הסכם סופי למימוש עסקי Endpoint Clinical ו-Patient Access בידי Arsenal Capital Partners
March 12, 2024 12:18 ET
|
Fortrea Holdings Inc
ההצעה לפיצול עסקי Endpoint Clinical ו-Fortrea Patient Access מייעלת עוד יותר את המיקוד האסטרטגי של Fortrea כארגון מחקר חוזי טהור ההסכם ייצור פתרונות עצמאיים הטובים מסוגם לניהול אספקת ניסויים ואקראיות...
Fortrea unterzeichnet endgültige Vereinbarung zur Veräußerung der Geschäftsbereiche Endpoint Clinical und Patient Access an Arsenal Capital Partners
March 12, 2024 12:18 ET
|
Fortrea Holdings Inc
Vorgeschlagene Veräußerung der Geschäftsbereiche Endpoint Clinical und Fortrea Patient Access optimiert Fortreas strategische Ausrichtung als reines Auftragsforschungsinstitut Schafft eigenständige,...
Fortrea signe un accord définitif pour céder les activités Endpoint Clinical et Patient Access à Arsenal Capital Partners
March 12, 2024 12:18 ET
|
Fortrea Holdings Inc
Le projet de cession des activités Endpoint Clinical et Fortrea Patient Access permet à Fortrea de se recentrer sur son cœur de métier stratégique d’organisme de recherche contractuelle Création de...
Fortrea, Arsenal Capital Partners에 Endpoint Clinical 및 Patient Access Business 매각하는 최종 계약 체결
March 12, 2024 12:18 ET
|
Fortrea Holdings Inc
Endpoint Clinical 및 Fortrea Patient Access 사업 매각 제안으로 순수 임상시험수탁기관으로서 Fortrea의 전략적 초점을 한층 간소화할 계획 업계 최고의 독립 무작위 배정 및 임상시험 공급 관리(RTSM) 솔루션 구축으로 차별화와 성장을 겨냥하다 더럼, 노스캐롤라이나, March 13, 2024 (GLOBE...
Fortrea 签署最终协议，将 Endpoint Clinical 和 Patient Access 业务剥离给 Arsenal Capital Partners
March 12, 2024 12:18 ET
|
Fortrea Holdings Inc
拟议剥离 Endpoint Clinical 和 Fortrea 患者通道 (Patient Access) 业务，进一步简化 Fortrea 的战略重心，成为纯粹的合同研究组织 创建独立的、一流的随机化 (Randomization) 和试验供应管理 (Trial Supply Management) 以及 Patient Access 解决方案，以实现差异化和增长 北卡罗来纳州，达勒姆市,...